title: Allogeneic bone marrow transplantation in models of experimental autoimmune encephalomyelitis: evidence for a graft-versus-autoimmunity effect.
abstract: Autologous hematopoietic stem cell transplantation (HSCT) is being explored in the treatment of severe multiple sclerosis (MS), and is based on the concept of "resetting" the immune system. The use of allogeneic HSCT may offer additional advantages, such as the replacement of the autoreactive immune compartment by healthy allogeneic cells and development of a graft-versus-autoimmunity (GVA) effect. However, in clinical practice, the genetic susceptibility to MS of allogeneic stem cell donors is generally unknown, and GVA may therefore be an important mechanism of action. Experimental autoimmune encephalomyelitis (EAE)-susceptible and -resistant mouse strains were used to determine the roles of genetic susceptibility, level of donor-chimerism, and alloreactivity in the therapeutic potential of syngeneic versus allogeneic bone marrow transplant (BMT) for EAE. After transplantation and EAE induction, animals were evaluated for clinical EAE and ex vivo myelin oligodendrocyte glycoprotein-specific proliferation. Early after BMT, both syngeneic and allogeneic chimeras were protected from EAE development. On the longer term, allogeneic but not syngeneic BMT conferred protection, but this required high-level donor-chimerism from EAE-resistant donors. Importantly, when EAE-susceptible donors were used, robust protection from EAE was obtained when active alloreactivity, induced by donor lymphocyte infusions, was provided. Our findings indicate the requirement of a sufficient level of donor-chimerism from a nonsusceptible donor in the therapeutic effect of allogeneic BMT. Importantly, the data indicate that, independently of genetic susceptibility, active alloreactivity is associated with a GVA effect, thereby providing new evidence to support the potential role of allogeneic BMT in the treatment of MS.
authors.affiliation: Laboratory of Experimental Transplantation, University of Leuven, Leuven, Belgium.
authors.forename: Bart
authors.initials: B
authors.lastname: Van Wijmeersch
authors.forename: Ben
authors.initials: B
authors.lastname: Sprangers
authors.forename: Omer
authors.initials: O
authors.lastname: Rutgeerts
authors.forename: Caroline
authors.initials: C
authors.lastname: Lenaerts
authors.forename: Willy
authors.initials: W
authors.lastname: Landuyt
authors.forename: Mark
authors.initials: M
authors.lastname: Waer
authors.forename: An D
authors.initials: AD
authors.lastname: Billiau
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Dubois
mesh_terms: D000818:Animals; D015551:Autoimmunity; D016026:Bone Marrow Transplantation / Q000379:methods*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000209:etiology* / Q000628:therapy*; D020022:Genetic Predisposition to Disease; D051379:Mice; D008810:Mice, Inbred C57BL; D018183:Transplantation Chimera; D014181:Transplantation Immunology; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic